Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
|Articles|December 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 12
- Volume 15
- Issue 12
Pharmion Purchases Cabrellis, US Developer of Amrubicin
Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.
Advertisement
BOULDER, ColoradoPharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.
Articles in this issue
almost 20 years ago
Best Rx Most Cost-Effective: RTOGalmost 20 years ago
Grape Seed Found to Be a Natural Aromatase Inhibitoralmost 20 years ago
Drug Combination Prevents ER-Negative Tumors in Micealmost 20 years ago
Democrats' Agenda May Stifle Efforts for More Ca Fundingalmost 20 years ago
No Loss of Efficacy With Synchronous Chemotherapy/ESPalmost 20 years ago
'Share Care' Difficult for Ca Survivors and Their Oncologistsalmost 20 years ago
Biomarkers Panel Promising for Detecting Pancreatic Caalmost 20 years ago
Preop Avastin/Tarceva in RCCalmost 20 years ago
Reovirus Agent Shows Activity in Phase I TrialAdvertisement
Related to this article
Medical oncologists, clinical pharmacists, and oncologic nurse practitioners share the presentation topics to look out for at WCLC 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
3
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
4
Novel Monoclonal Antibody Wins FDA Fast Track Designation in High-Risk MDS
5